| Symbol | DGNOF |
|---|---|
| Name | DIAGNOS INC. |
| Sector | UNDEFINED |
| Region | North America |
| Industry | - |
| Address | J4Z 1A7 Canada QC 7005 Taschereau Boulevard Suite 265 |
| Telephone | +1 450-678-8882 |
| Fax | — |
| — | |
| Website | http://www.diagnos.ca |
| Incorporation | CA |
| Incorporated On | 1996 |
| Employees | — |
| Fiscal Year | 3/31 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | Raymond Chabot Grant Thornton; |
| Audit Status | AUDITED |
| Reporting Status | International Reporting: TSX Venture Exchange |
| CIK | — |
| Description | DIAGNOS is a publicly traded Canadian corporation dedicated to early detection of critical eye-related health problems through the use of its FLAIRE Artificial Intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications such as CARA (Computer Assisted Retina Analysis). CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care (POC). CARA image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a cost-effective tool for screening large numbers of patients in real-time. Additional info from OTC: |
No news found.